NCT06578000 Efficacy of Iontophoresis in Treating Lateral Epicondylitis Patients
| NCT ID | NCT06578000 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | NOUR ALI ABO EL ELAA FRAGHLY |
| Condition | Lateral Epicondylitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-09-01 |
| Primary Completion | 2024-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 40 participants in total. It began in 2024-09-01 with a primary completion date of 2024-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is conducted To evaluate the effect of magnesium sulfate on pain intensity, muscle power, hand grip and function ability in patients with lateral epicondylitis.
Eligibility Criteria
Inclusion Criteria: * • Their age will be ranged between 20-50 years with both gender * Pain on the lateral side of the elbow for at least 4 weeks * Tenderness over the lateral epicondyle * At least two positive provocative tests: Mill test and Thomson test Exclusion Criteria: * • History of injection, surgery, physical therapy in the elbow area in the last 3 months * Previous elbow surgery * History of radius/ulna fracture * History of cervical and shoulder problems * Having bilateral symptoms * Concomitant medial epicondylitis * Malignancy * Pregnancy * Systemic rheumatologic disease or systemic infection * Inserted cardiac pacemaker * Presence of coagulation disorders * Cognitive dysfunction
Contact & Investigator
Neveen Abd El latif Abdel Raoof, professor
STUDY DIRECTOR
Professor of Physical Therapy department for Basic sciences
Frequently Asked Questions
Who can join the NCT06578000 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Lateral Epicondylitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06578000 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06578000 currently recruiting?
Yes, NCT06578000 is actively recruiting participants. Contact the research team at noor.ali@pt.seuz.edu.eg for enrollment information.
Where is the NCT06578000 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06578000 clinical trial?
NCT06578000 is sponsored by NOUR ALI ABO EL ELAA FRAGHLY. The principal investigator is Neveen Abd El latif Abdel Raoof, professor at Professor of Physical Therapy department for Basic sciences. The trial plans to enroll 40 participants.